1 / 23

Journal Club

Journal Club. Shin A, Camilleri M, Busciglio I, Burton D, Stoner E, Noonan P, Gottesdiener K, Smith SA, Vella A, Zinsmeister AR.

guido
Download Presentation

Journal Club

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Journal Club Shin A, Camilleri M, Busciglio I, Burton D, Stoner E, Noonan P, Gottesdiener K, Smith SA, Vella A, Zinsmeister AR. Randomized Controlled Phase Ib Study of Ghrelin Agonist, RM-131, in Type 2 Diabetic Women With Delayed Gastric Emptying: Pharmacokinetics and pharmacodynamics. Diabetes Care. 2013 Jan;36(1):41-8. doi: 10.2337/dc12-1128. 埼玉医科大学　総合医療センター　内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University 松田　昌文 Matsuda, Masafumi 2013年1月31日8:30-8:55 ８階　医局

  2. Ghrelin / obstatin Ghrelin is a 28 amino acid hunger-stimulating peptide and hormone that is produced mainly by P/D1 cells lining the fundus of the human stomach and epsilon cells of the pancreas. Ghrelin together with obestatin is produced from cleavage of the ghrelin/obestatinprepropeptide (also known as the appetite-regulating hormone or growth hormone secretagogue or motilin-related peptide) which in turn is encoded by the GHRL gene. Ghrelin levels increase before meals and decrease after meals. It is considered the counterpart of the hormone leptin, produced by adipose tissue, which induces satiation when present at higher levels. In some bariatric procedures, the level of ghrelin is reduced in patients, thus causing satiation before it would normally occur. 1999年、国立循環器病センターの児島将康・寒川賢治らにより発見された 分子量：3370.9 アミノ酸配列：1 GSSFLSPEHQRVQQRKESKKPPAKLQPR 28 The mRNA from the GHRL gene codes for a 117 amino acid peptide called preproghrelin, containing 4 exons. The signalling peptide molecule of this larger precursor is cleaved to produce proghrelin. Proghrelin is cleaved in two to produce the 28 amino acid peptide ghrelin (unacylated) and C-ghrelin (of which obestatin is presumed to be a cleaved form). obestatin NMR structure in SDS/DPC micellar solution http://en.wikipedia.org/wiki/Ghrelin

  3. http://www.japan-acad.go.jp/japanese/news/2008/031201.html GSK894490A CP-464709-18 認識力増大 Capromorelin GHRP-2 GHRP-6 Hexarelin Ipamorelin MK-677 SM-130,686 Tabimorelin TZP-101 RM-131　グレリンより100倍強力！ AEZS-130 ONO-7643 など http://en.wikipedia.org/wiki/Growth_hormone_secretagogue_receptor

  4. http://www.rhythmtx.com/PROGRAMS/RM131.html

  5. the 1Division of Gastroenterology and Hepatology, Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), College of Medicine, Mayo Clinic, Rochester, Minnesota; 2Rhythm Pharmaceuticals, Boston, Massachusetts; the 3Division of Endocrinology, Nutrition, and Metabolism, College of Medicine, Mayo Clinic, Rochester, Minnesota; and the 4Department of Health Sciences Research, Division of Biomedical Statistics and Informatics, College of Medicine, Mayo Clinic, Rochester, Minnesota. Diabetes Care 36:41–48, 2013

  6. OBJECTIVE To investigate the pharmacokinetics (PK), pharmacodynamics, and safety of single-dose RM-131 in type 2 diabetic patients with gastrointestinal cardinal symptoms (GCSI) and previously documented delayed gastric emptying (DGE).

  7. RESEARCH DESIGN AND METHODS In a randomized crossover study, 10 female patients received RM-131 (100 mg s.c.) or placebo and underwent scintigraphic gastric emptying (GE) and colonic filling at 6 h (CF6) of a solid-liquid meal administered 30 min postdosing. Adverse events, plasma glucose, and hormonal levels were assessed. GCSI daily diary (GCSI-DD) was completed during treatments. PK was assessed in this cohort and healthy volunteers (HVs).

  8. PD evaluations included upper GI motility evaluation by scintigraphy. Patients received a subcutaneous injection of RM-131 or placebo (5% mannitol), which had identical appearance. After a 7-day washout period, patients crossed over to receive the alternative therapy Supplementary Figure 1. Patient disposition using CONSORT approach; all participants completed all studies, and data were analyzed using intention to treat principles.

  9. Patients received a subcutaneous injection of RM-131 or placebo (5% mannitol), which had identical appearance. Thirty minutes after subcutaneous administration of the study drug, a standardized radiolabeled study meal was administered, which patients were asked to consume within 10 min. The study meal consisted of the following: 4 oz. of scrambled Egg Beaters that had been radiolabeled with 0.5–1.0 mCi of 99mTc sulfur colloid; 120 mL of water that had been radiolabeled with 100 mCi of 111In diethylenetriaminepentaacetic acid; and two slices of white bread with strawberry jam. Gamma scans were obtained immediately after completion of the study meal through 6 h postmeal. Postinjectionblood sampling for postdose GH, insulin, prolactin, and cortisol levels were collected. PK(pharmacokinetics) was also collected through 6 h postdose.

  10. Supplementary Figure 2 Change in GE t1/2 solid by treatment period for each individual patient [gastric emptying (GE), minutes for solids for all 10 patients by treatment period (placebo and RM-131)]. Data are individual observations for each patient. Patient numbers correspond to the listing in Table 1 in the paper. Median and IQR for healthy volunteers reported in the literature (ref. 27 in paper) are indicated in the figure.

  11. Figure 1Effect of RM-131 on main transit measurements (GE, minutes for solids and liquids, and CF6, percent). Top: Data in all 10 patients. White bars, placebo; black bars, RM-131, 100 mg, treatment. Data are mean ±SEM. P values by the Student paired t test comparing RM-131 vs. placebo above each comparison (top) and by the Student unpaired t test comparing RM-131 vs. placebo (bottom). Published normal data (28) with this meal show t1/2 solid of median 83 min (IQR 64–103 min).

  12. Figure 1Effect of RM-131 on main transit measurements (GE, minutes for solids and liquids, and CF6, percent). Bottom: Analysis of data in period 1 only (n = 5 per group; see text for details). White bars, placebo; black bars, RM-131, 100 mg, treatment. Data are mean ± SEM. P values by the Student paired t test comparing RM-131 vs. placebo above each comparison (top) and by the Student unpaired t test comparing RM-131 vs. placebo (bottom). Published normal data (28) with this meal show t1/2 solid of median 83 min (IQR 64–103 min).

  13. Supplementary Figure 3. Effect of RM-131 on plasma hormonal measurements [growth hormone (GH), prolactin, and cortisol] summarized as the 30-90 minute area under the plasma concentration curve. white bars = placebo; black bars = RM-131, 100μg, treatment. Data are mean+SEM; p values by the paired t test comparing RM-131 versus placebo above each comparison.

  14. RM-131 was generally well tolerated. Although the total number of adverse events (P = 0.016 using McNemar test) recorded was higher with RM-131 (Supplementary Table 1), there were no serious adverse effects and no obvious pattern to the adverse effects, and only light-headedness was reported more often on RM-131. All adverse effects resolved spontaneously. No clinically significant effects on physical examination, ECG parameters, vital signs, or routine hematology and chemistry laboratory tests were observed.

  15. RESULTS At screening, HbA1c was 7.2 ± 0.4% (SEM) and total GCSI-DD score was 1.32 ±0.21. RM-131 accelerated GE t1/2 of solids (P = 0.011); mean difference (D) in solid GE t1/2was 68.3 min (95% CI 20–117) or 66.1%. There were numerical differences in GE lag time, CF6 solids, and GE t1/2liquids (all P ＜0.14). With a significant (P ＜0.014) order effect, further analysis of the first treatment period (n = 5 per group) confirmed significant RM-131 effects on GE t1/2(solids, P = 0.016; liquids, P = 0.024;CF6, P = 0.013). PK was similar in DGE patients and HVs. There were increases in 120-min blood glucose (P = 0.07) as well as 30–90-min area under the curve (AUC) levels of growth hormone, cortisol, and prolactin (all P＜0.02) with single-dose RM-131. Only light-headedness was reported more on RM-131.

  16. CONCLUSIONS RM-131 greatly accelerates the GE of solids in patients with type 2 diabetes and documented DGE. PK is similar in diabetic patients and HVs.

  17. Message グレリンは食欲を増すので神経性食思不振症に効くかもしれない。とりあえずグレリン作動薬は胃の動きをよくしてくれるだろう。 実際にこの研究ではそのような結論である。ちょっとAdverse eventsが多いようにも感じる。で、六君子湯でも効くのか？ともかくグレリン受容体作動薬はたくさんある！ しかし、グレリンは食欲を増すので逆に阻害薬があれば食欲を減らしてきっと糖尿病の治療に役に立つと思われるけれど．．．

More Related